Study of selenium-related markers in triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks at “selenoproteins” (protein markers in the body) to understand how triple-negative breast cancer behaves and whether they could be targets for future treatments. You may be asked to provide samples before any cancer drug treatment to see if these markers predict outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer
- You have not started any cancer drug treatment yet
- You are a woman between ages 25 and 60
- You are not currently being treated for another cancer and have no past cancers
- You do not have diabetes, hypertension (high blood pressure), heart disease, or active infections
- You do not have HIV, hepatitis B, or hepatitis C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
This study looks at how your immune system responds to triple-negative breast cancer. It will test your blood or tissue to learn more about your body's natural defenses against the cancer.
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.